WO2018145005A1 - Tube de collecte d'échantillon avec conservateur - Google Patents

Tube de collecte d'échantillon avec conservateur Download PDF

Info

Publication number
WO2018145005A1
WO2018145005A1 PCT/US2018/016867 US2018016867W WO2018145005A1 WO 2018145005 A1 WO2018145005 A1 WO 2018145005A1 US 2018016867 W US2018016867 W US 2018016867W WO 2018145005 A1 WO2018145005 A1 WO 2018145005A1
Authority
WO
WIPO (PCT)
Prior art keywords
tube
blood collection
collection tube
reagent
blood
Prior art date
Application number
PCT/US2018/016867
Other languages
English (en)
Inventor
Brad HUNSLEY
John Noble
Original Assignee
Streck, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Streck, Inc. filed Critical Streck, Inc.
Priority to CN201880023537.6A priority Critical patent/CN110520045A/zh
Priority to EP18747249.3A priority patent/EP3576625A4/fr
Publication of WO2018145005A1 publication Critical patent/WO2018145005A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N1/00—Preservation of bodies of humans or animals, or parts thereof
    • A01N1/02—Preservation of living parts
    • A01N1/0236—Mechanical aspects
    • A01N1/0263—Non-refrigerated containers specially adapted for transporting or storing living parts whilst preserving, e.g. cool boxes, blood bags or "straws" for cryopreservation
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
    • B01L3/00—Containers or dishes for laboratory use, e.g. laboratory glassware; Droppers
    • B01L3/50—Containers for the purpose of retaining a material to be analysed, e.g. test tubes
    • B01L3/508—Containers for the purpose of retaining a material to be analysed, e.g. test tubes rigid containers not provided for above
    • B01L3/5082—Test tubes per se
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/15—Devices for taking samples of blood
    • A61B5/150007—Details
    • A61B5/150015—Source of blood
    • A61B5/15003—Source of blood for venous or arterial blood
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/15—Devices for taking samples of blood
    • A61B5/150007—Details
    • A61B5/150351—Caps, stoppers or lids for sealing or closing a blood collection vessel or container, e.g. a test-tube or syringe barrel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/15—Devices for taking samples of blood
    • A61B5/153—Devices specially adapted for taking samples of venous or arterial blood, e.g. with syringes
    • A61B5/154—Devices using pre-evacuated means
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
    • B01L2200/00—Solutions for specific problems relating to chemical or physical laboratory apparatus
    • B01L2200/14—Process control and prevention of errors
    • B01L2200/141—Preventing contamination, tampering
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
    • B01L2300/00—Additional constructional details
    • B01L2300/04—Closures and closing means
    • B01L2300/041—Connecting closures to device or container
    • B01L2300/042—Caps; Plugs
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
    • B01L2300/00—Additional constructional details
    • B01L2300/08—Geometry, shape and general structure
    • B01L2300/0832—Geometry, shape and general structure cylindrical, tube shaped
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
    • B01L2300/00—Additional constructional details
    • B01L2300/16—Surface properties and coatings

Definitions

  • the present teachings relate generally to containers, and more particularly to polymeric tubes for biomedical sample collection, storage, transport and analysis.
  • biomedical sample collection tubes which meet certain performance standards and are suitable for use in biomedical testing and analysis. There is a need for biomedical sample collection tubes which do not interact or alter any reagent enclosed in the tube. There is a further need for biomedical sample collection tubes which do not alter certain critical properties of the intended biomedical sample. There is a need for biomedical sample collection tubes which maintain a vacuum for a prolonged period of time, especially in conditions that the sample collection tube may experience during shipping. Such needs are particularly acute in blood sample collection and analysis.
  • polymeric containers may be coated with a coating covering the interior surface of the container.
  • the coating may be deposited onto the polymeric substrate by plasma enhanced chemical vapor deposition (PECVD).
  • PECVD is a process used to deposit films from a gas state to a solid state on a substrate. Examples of polymeric containers with coatings include those in U.S. Pat.
  • the present teachings meet one or more of the above needs by providing an improved polymeric tube for blood sample collection, storage, transport and analysis.
  • the blood collection sample tube includes a tube having an enclosed base, a coextensive elongated side wall extending from the base and terminating at an open end, and defining a hollow chamber having an inner wall, the hollow chamber being configured for collecting a blood sample, at least the elongated side wall of the tube being made of a material including a thermoplastic polymeric material having a high moisture barrier and low moisture absorption rate, optical transparency to enable viewing a sample within the tube and chemical resistance; and optionally a transparent silicon-containing coating on at least a majority of the side wall of the tube; and an elastomeric stopper.
  • the hollow chamber of the tube Prior to collecting the blood sample, the hollow chamber of the tube is in an evacuated condition relative to an ambient pressure, and the hollow chamber is at least partially filled with a reagent in an initial state selected from a solid, a liquid, or a gel, the reagent including an optional anticoagulant, and a preservative composition adapted for stabilizing blood cells of the blood sample for enabling isolation of a nucleic acid or a rare cell/material circulating in the blood sample.
  • the reagent is capable of retaining its initial state for a period of at least one month over a temperature range of about 2 °C to about 30 °C.
  • the polymeric material may include a cyclic polyolefin.
  • the polymeric material may include cyclic polyolefin copolymer (COC).
  • the polymeric material may include cyclic polyolefin polymers (COP).
  • the tube may be part of a kit adapted for a non-invasive testing of a maternal blood sample of a pregnant woman.
  • the elongated side wall of the tube may terminate at the open end in an annular rim that is optionally enlarged relative to the sidewall and is otherwise configured so that in combination with the stopper, the stopper is restricted from separation from the tube when subjected to conditions simulating a 95 kPa pressure differential for at least 30 minutes, a temperature below about 30 °C, or both; wherein the evacuated condition of the tube is capable of being maintained for at least 24 months from date of an initial evacuation of the tube.
  • the structure of the tube including its closure mechanism promotes maintaining the necessary pressure within the tube, despite fluctuations in the environment during tube transport. Such fluctuations may include changes in temperature, changes in air pressure, changes in humidity and other environmental factors. More specifically, the tube must remain securely closed despite decreased humidity and decreased air pressure that may occur at higher altitudes.
  • the stopper may include bromobutyl rubber.
  • the stopper of the tube may include a silicone oil coating over at least a portion of its outer surface that contacts the inner wall of the tube.
  • the base may include a recessed dimple.
  • At least the inner wall of the tube may taper in diameter towards a base.
  • the tube may have an outer diameter, as measured at the coextensive elongated side wall adjacent the open end, to length (D x L) dimension of about 13 mm x 75 mm.
  • the tube may have an outer diameter, as measured at the coextensive elongated side wall adjacent the open end, to length (D x L) dimension of about 16 mm X 100 mm.
  • the tube may include a reagent fill tolerance volume of about 54 ⁇ to about 66 ⁇ .
  • the tube may include a reagent fill tolerance volume of about 60 ⁇ .
  • the tube may include a reagent fill tolerance volume of about 162 ⁇ to about 198 ⁇ .
  • the tube may include a reagent fill tolerance volume of about 180 ⁇ .
  • the tube may include a reagent fill by weight of plus or minus 10% of 0.0708g.
  • the tube may include a reagent fill by weight of plus or minus 10% of 0.224g.
  • the tube may include a draw tolerance of about 3 ml to about 5 ml.
  • the tube may include a draw tolerance of about 4 ml.
  • the tube may include a draw tolerance of about 7 ml to about 13 ml.
  • the tube may include a draw tolerance of about 9 ml.
  • the preservative composition may contain less than about 20 parts per million (ppm) of an aldehyde per 100 ⁇ of the preservative composition.
  • the preservative composition may contain less than about 15 parts per million (ppm) of an aldehyde per 100 ⁇ of the preservative composition.
  • the preservative composition may contain less than about 10 parts per million (ppm) of an aldehyde per 100 ⁇ of the preservative composition.
  • the preservative composition may contain less than about 5 parts per million (ppm) of an aldehyde per 100 ⁇ of the preservative composition.
  • the preservative composition may contain at least about 0.1 parts per million (ppm) to about 20 ppm of an aldehyde per 100 ⁇ of the preservative composition.
  • the preservative composition may contain at least about 0.5 parts per million (ppm) to about 15 ppm of an aldehyde per 100 ⁇ of the preservative composition.
  • the preservative composition may contain at least about 1 parts per million (ppm) to about 10 ppm of an aldehyde per 100 ⁇ of the preservative composition.
  • the aldehyde may include formaldehyde.
  • the polymeric material may have a moisture vapor transmission rate of about 0.023 g ⁇ mm/ m 2 ⁇ d to about 0.045 g ⁇ mm/ m 2 ⁇ d at 23 °C and 85% relative humidity, as measured by DIN 53 122.
  • the polymeric material may have a tensile strength of about 60 MPa to about 63 MPa, as measured by ISO 527, parts 1 and 2.
  • the polymeric material may have a tensile modulus of about 2300 MPa to about 2600 MPa, as measured by ISO 527, parts 1 and 2.
  • the polymeric material may have an impact strength (Charpy Impact Unnotched) of about 20 kJ/m2 as measured by ISO 179/1 ell.
  • the polymeric material may have a light transmission of at least about 90%.
  • the polymeric material may have a mold shrinkage of about 0.1 % to about 0.7%.
  • the tube may have an average wall thickness along its length of about 2.0 mm.
  • the coating may have an average thickness throughout the tube of about 100 nm to about 500 nm.
  • the polymeric material may have a birefringence of less than 20 nm according to ASTM D4093-95.
  • the polymeric material may have a glass transition temperature of about 78 °C to about 136 °C as measured by differential scanning calorimetry (DSC).
  • the polymeric material and coating may each have coefficients of thermal expansion that are within about twenty percent of each other.
  • the polymeric material may include a homopolymer or copolymer that includes polyethylene, polypropylene or both.
  • the polymeric material may include a cyclic moiety.
  • the polymeric material may include a polyester.
  • the preservative may be selected from the group consisting of formaldehyde, diazolidinyl urea (DU), imidazolidinyl urea (IDU), dimethylol urea, 2- bromo-2-nitropropane-1 ,3-diol, 5-hydroxymethoxymethyl-1 -aza-3,7-dioxabicyclo
  • the anticoagulant or enzyme inhibitor may be EDTA.
  • the tube may be suitable for storing a blood sample for a period of at least about 14 days.
  • a blood sample stored in the tube having a silicon containing coating may result in a substantial increase in the amount of recoverable nucleic acid or rare cells (e.g., DNA, RNA, extracellular vesicles, circulating tumor cells, circulating rare cells or proteins) as compared with a polymeric tube of the same polymer but with no coating and the substantial increase may be at least about 10%.
  • a blood sample stored in the tube having a silicon-containing coating may result in a substantial increase in the amount of recoverable nucleic acid or rare cells as compared with a polymeric tube of the same polymer but with no coating and the substantial increase may be at least about 20%.
  • a blood sample stored in the tube having a silicon-containing coating may result in a substantial increase in the amount of recoverable nucleic acid or rare cells as compared with a polymeric tube with no coating and the substantial increase may be at least about 30%.
  • the tube may include an adhesive-backed label adhered to an outer wall of the tube, and the adhesive may be an acrylic based adhesive.
  • the reagent in the tube may include about 15% to about 70% by volume of the preservative composition prior to blood draw.
  • the reagent in the tube may include about 15% to about 70% by volume of imidazolidinyl urea (IDU) prior to blood draw.
  • the reagent in the tube include may include about 5% to about 20% by volume of anticoagulant prior to blood draw.
  • the reagent in the tube may include about 5% to about 20% of anticoagulant prior to blood draw.
  • the reagent in the tube may include about 1 % to about 10% of an agent in addition to the preservative and an anticoagulant prior to blood draw.
  • the tube may include an amount of aldehyde reaction agent for reacting with free formaldehyde present in the reagent sufficient to result in an aldehyde amount below 20 ppm per 100 ⁇ of reagent prior to blood draw.
  • the tube may include an amount of aldehyde reaction agent containing a primary amine for reacting with free formaldehyde present in the reagent to result in an aldehyde amount below 20 ppm per 100 ⁇ of reagent prior to blood draw.
  • the tube may include an amount of aldehyde reaction agent, which aldehyde reaction agent is selected from one or any combination of tris, glycine, or a derivative (e.g., a salt and/or an ester) of either or both, for reacting with free formaldehyde present in the reagent to result in an aldehyde amount below 20 ppm per 100 ⁇ of reagent prior to blood draw.
  • aldehyde reaction agent is selected from one or any combination of tris, glycine, or a derivative (e.g., a salt and/or an ester) of either or both, for reacting with free formaldehyde present in the reagent to result in an aldehyde amount below 20 ppm per 100 ⁇ of reagent prior to blood draw.
  • the aldehyde reaction agent may be present in a ratio (by weight) relative to the preservative composition of about 1 :20 to about 1 : 1 .
  • the aldehyde reaction agent may be present in a ratio (by weight) relative to the anticoagulant of about 1 :25 to about 5: 1 .
  • the preservative composition may be present in a ratio (by weight) relative to the anticoagulant of about 1 : 10 to about 15:1 .
  • the reagent may be present in the tube as a liquid in an amount less than about 10% by volume of the tube but greater than about 0.1 % by volume.
  • the reagent may be present in the tube as a liquid in an amount less than about 5% by volume of the tube but greater than about 0.1 % by volume of the tube.
  • the reagent may be present in the tube in an amount less than about 3% by volume of the tube but greater than about 0.1 % by volume of the tube.
  • the tube may include a reagent with one or more ingredients and a ratio of the one or more ingredients may be about 5: 1 to about 15: 1.
  • the tube may include imidazolidinyl urea (IDU) and glycine and a ratio of imidazolidinyl urea (IDU) to glycine may be about 10: 1 .
  • the reagent may be capable of retaining its initial state for a period of at least one month over a temperature range of about 2 °C to about 30 °C when the tube is subjected to relative humidity of up to about least about 50%.
  • the reagent may be capable of retaining its initial state for a period of at least one month over a temperature range of about 2 °C to about 30 °C when the tube is subjected to relative humidity of up to about 75%.
  • the reagent in the tube may include about 60% to about 90% by volume diazolidinyl urea (DU) prior to blood draw.
  • the reagent in the tube includes about 15% to about 35% of anticoagulant prior to blood draw.
  • a blood collection sample tube comprising a tube having an enclosed base, a coextensive elongated side wall extending from the base and terminating at an open end, and defining a hollow chamber having an inner wall, the hollow chamber being configured for collecting a blood sample, at least the elongated side wall of the tube being made of a material including a thermoplastic polymeric material having a moisture barrier and low moisture absorption rate, optical transparency to enable viewing a sample within the tube and chemical resistance, an elastomeric stopper, and blood plasma including cell-free nucleic acids and a reagent located within the tube, the reagent including an optional anticoagulant, formaldehyde, and a preservative composition.
  • FIG.1 is a front view of an illustrative example of a blood collection tube assembly of the present teachings.
  • FIG. 2(a) is a front view of an illustrative example of a 4 ml blood collection tube of the present teachings.
  • FIG. 2(b) is a close-up view of portion B of the tube of FIG. 2(a) depicting the upper portion of the tube terminating at an open end and including an annular rim.
  • FIG. 2(c) is a close-up view of portion C of the tube of FIG. 2(a) depicting the lower portion of the tube including a base and recessed dimple.
  • FIG. 3(a) is a front view of an illustrative example of a 10 ml blood collection tube of the present teachings.
  • FIG. 3(b) is a close-up view of portion B of the tube of FIG. 3(a) depicting the upper portion of the tube terminating at an open end and including an annular rim.
  • FIG. 3(c) is a close-up view of portion C of the tube of FIG. 3(a) depicting the lower portion of the tube including a base and a recessed dimple.
  • FIG. 4(a) is a graph depicting the draw volume results of twenty 9 ml blood collection tubes of the present teachings.
  • FIG. 4(b) is a graph depicting the draw volume results of twenty 4 ml blood collection tubes of the present teachings.
  • FIG. 5 is a graph depicting cell-free DNA genome equivalents per 1 ml_ of plasma for a storage temperature study at 6 ⁇ 2 °C for glass blood collection tubes and the blood collection tubes of the present teachings.
  • FIG. 6 is a graph depicting cell-free DNA genome equivalents per 1 ml_ of plasma for a storage temperature study at 18-25 °C for glass blood collection tubes and the blood collection tubes of the present teachings.
  • FIG. 7 is a graph depicting cell-free DNA genome equivalents per 1 ml_ of plasma for a storage temperature study at 37 ⁇ 2 °C for glass blood collection tubes and the blood collection tubes of the present teachings.
  • FIG. 8 is a graph depicting cell-free DNA genome equivalents per 1 ml_ of plasma for a shipping and handling study for glass blood collection tubes and the blood collection tubes of the present teachings.
  • FIG. 9(a) is a graph depicting oxygen transmission rate constants for polyethylene terephthalate (PET) tubes and 9 ml blood collection tubes of the present teachings.
  • FIG. 9(b) is a graph depicting oxygen transmission rate constants for polyethylene terephthalate (PET) tubes and 4 ml blood collection tubes of the present teachings.
  • FIG. 10(a) is a graph depicting theoretical draw volumes for polyethylene terephthalate (PET) tubes and 9 ml blood collection tubes of the present teachings over 24 months.
  • FIG. 10(b) is a graph depicting theoretical draw volumes for polyethylene terephthalate (PET) tubes and 4 ml blood collection tubes of the present teachings over
  • FIG. 1 1 is a graph depicting moisture loss for polyethylene terephthalate (PET) tubes and the blood collection tubes of the present teachings over 28 days at 18-
  • FIG. 12 is a graph depicting the results of a comparative analysis moisture vapor barrier study at 85 days at 22 °C, 30 °C and 50 °C of commercial plastic blood collection tubes and blood collection tubes of the present teachings.
  • the present teachings pertain generally to an improved polymeric tube for biomedical sample collection, storage, transport and analysis.
  • the polymeric tube is particularly attractive for blood sample collection.
  • the sample collection tube of the present teachings may resist adherence of the contents of the collected biomedical sample to the walls of the sample collection tube.
  • the interior surface of the blood collection tube may resist adherence to blood cells of the drawn blood sample.
  • the blood collection tube may resistance adherence of nucleic acids or other biological material (e.g. DNA, RNA, extracellular vesicles, circulating tumor cells, circulating rare cells or proteins) of the drawn blood sample to the walls of the tube.
  • the blood collection sample tube includes a tube having an enclosed base, a coextensive elongated side wall extending from the base and terminating at an open end, and defining a hollow chamber having an inner wall, the hollow chamber being configured for collecting a blood sample, at least the elongated side wall of the tube being made of a material including a thermoplastic polymeric material having a moisture barrier and low moisture absorption rate, optical transparency to enable viewing a sample within the tube and chemical resistance; and optionally a transparent silicon-containing coating on at a majority of the side wall of the tube; and an elastomeric stopper.
  • the hollow chamber of the tube Prior to collecting the blood sample, the hollow chamber of the tube is in an evacuated condition relative to an ambient pressure, and the hollow chamber is partially filled with a reagent in an initial state selected from a solid, a liquid or a gel.
  • the reagent may include an optional anticoagulant, and a preservative composition adapted for stabilizing blood cells of the blood sample for enabling isolation of a nucleic acid or a rare cell circulating in the blood sample.
  • the reagent is capable of retaining its initial state for a period of at least one month over a temperature range of about 2 °C to about 30 °C.
  • the blood sample collection tube is a single use tube.
  • the blood sample collection tube is non-pyrogenic and/or endotoxin free.
  • the blood collection tube may be used to collect blood samples for analytical purposes.
  • the blood sample collection tube may be an evacuated direct draw blood collection tube which is used for stabilization and preservation of a blood sample and/or blood sample components.
  • the blood sample collection tubes may be used for the stabilization and preservation of nucleic acids.
  • the nucleic acid may include but is not limited to the following: genomic DNA, cell-free DNA, methlylated DNA, cellular RNA, mRNA and cell-free RNA.
  • the blood collection tubes of present teachings may be used for non-invasive prenatal testing (NIPT) which analyzes cell-free fetal DNA circulating in maternal blood.
  • the prenatal tests may include fetal sex determination, genetic screening for one or more chromosomal conditions (e.g. trisomy) and prenatal DNA paternity testing.
  • the tube may be part of a kit adapted for a non-invasive testing of a maternal blood sample of a pregnant woman.
  • the blood sample collection tubes may be used for the stabilization and preservation of one or more of the following: proteins, enzymes and antibodies, including with and without post-translational modifications. For example, for analysis by one or more of the following: surface flow cytometry, intracellular cytometry, ELISA-based assays and mass spectrometry.
  • the blood sample collection tubes may be used for the stabilization and preservation of exosomes and/or microparticles.
  • the blood sample collection tubes may be used for the stabilization and preservation of viruses. This may include viral inactivation and viral load quantification.
  • the virus may include any of the following: DNA/RNA, stranded/double stranded and enveloped/non-enveloped.
  • the blood sample collection tubes may be used for the stabilization and preservation of microorganisms such as bacteria, molds and yeasts.
  • the blood sample collection tubes may be used for the stabilization and preservation of extracellular parasites and/or intracellular parasites.
  • the blood sample collection tubes may be used for the stabilization and preservation of circulating tumor cells and tumor DNA.
  • Evacuated blood collection tubes typically have an expiration date. An expired tube may have a decreased vacuum, resulting in a short blood draw and leading to an improper blood to reagent ratio. Thus, it is important that a blood collection tube be able to maintain a vacuum for an extended period of time.
  • the blood collection tube of the present teachings may provide an evacuated blood collection tube which maintains a vacuum for an extended period of time (e.g. at least 24 months). Furthermore, the draw tolerance of the blood collection tube should be accurate, (e.g. +/- 10% of ml of the stated collection volume).
  • the blood collection tube may be adapted for used with a stopper.
  • the stopper may include an elastomeric material.
  • the stopper may include a butyl rubber derivative.
  • the stopper may include a halogenated butyl.
  • the stopper may include bromobutyl rubber.
  • the stopper may include pharmaceutical bromobutyl rubber.
  • the stopper may be utilized with stopper lubricant.
  • the stopper may be coated.
  • the stopper may be partially coated.
  • the coating may include silicone.
  • the stopper of the tube may include a silicone oil coating over at least a portion of its outer surface that contacts the inner wall of the tube.
  • the present teachings contemplate a blood collection tube assembly including the blood collection tube of the present teachings and a stopper. It is contemplated that the seal or interface of the outer wall of the cap and the inner wall of the tube is such that the moisture transmission rate is substantially reduced. It is contemplated that the seal or interface of the outer wall of the stopper and the inner wall of the tube is such that the oxygen transmission rate is substantially reduced. An effective seal should provide both a moisture barrier and a gas barrier.
  • the present teachings provide a blood collection tube assembly in which the stopper resists pull out from the opening of the tube.
  • the present teachings provide a blood collection assembly which provide both an effective moisture transmission barrier thereby preventing moisture from escaping from inside of a tube filled with reagent and an effective oxygen transmission barrier thereby preventing penetration of oxygen into the tube.
  • the elongated side wall of the tube may terminate at the open end in an annular rim that is optionally enlarged relative to the sidewall and is otherwise configured so that in combination with the stopper, the stopper is restricted from separation from the tube when subjected to conditions simulating a 95 kPa pressure differential for at least 30 minutes, a temperature below about 30 °C, or both; wherein the evacuated condition of the tube is capable of being maintained for at least 24 months from date of an initial evacuation of the tube.
  • the reagent may be capable of retaining its initial state (e.g., liquid, gel, solid) for a period of at least one month over a temperature range of about 2 °C to about 30 °C when the tube is subjected to relative humidity of up to about least about 50%.
  • the reagent may be capable of retaining its initial state for a period of at least one month over a temperature range of about 2 °C to about 30 °C when the tube is subjected to relative humidity of up to about 75%.
  • the tube includes an enclosed base, a coextensive elongated side wall extending from the base and terminating at an open end, and defining a hollow chamber having an inner wall, the hollow chamber being configured for collecting a blood sample.
  • the elongated side wall of the tube terminates at the open end in an annular rim.
  • the base of the blood collection tube may be cup shaped.
  • the base of the blood collection tube may include an indentation.
  • the base of the blood collection tube may include a recess which projects inwardly into the tube.
  • the upper portion of the blood collection tube may include one or more indentations along the exterior surface of the tube.
  • the upper portion of the blood collection tube may include one or more indentations along the interior surface of the tube.
  • the blood collection tube may slightly taper along the length of the tube.
  • the diameter of the tube as measured at the coextensive elongated side wall adjacent the open end may differ from the diameter of the tube as measured at the coextensive side wall adjacent the base.
  • the diameter may differ from about .25 mm to about 3 mm.
  • the diameter as measured at the coextensive side wall adjacent the open end may be greater than the diameter of the tube as measured at the coextensive side wall adjacent the base.
  • the diameter as measured at the coextensive side wall adjacent the open end may be less than the diameter of the tube as measured at the coextensive side wall adjacent the base.
  • At least the inner wall of the tube may taper in diameter towards a base.
  • the sample collection tube's dimensions may be about 13 mm X 75 mm.
  • the tube may have an outer diameter, as measured at the coextensive elongated side wall adjacent the open end, to length (D x L) dimension of about 13 mm x 75 mm.
  • the sample collection tube's dimensions may be about 16 mm X 100 mm.
  • the tube may have an outer diameter, as measured at the coextensive elongated side wall adjacent the open end, to length (D x L) dimension of about 16 mm X 100 mm.
  • the sample collection tube's dimensions may be about 13 mm X 100 mm.
  • the tube may have an outer diameter, as measured at the coextensive elongated side wall adjacent the closed end, to length (D x L) dimension of about 13 mm X 100 mm.
  • the blood collection tube may have a wall thickness of about 2 mm.
  • the blood collection tube may have a wall thickness of about 1 .5 mm to about 2.5 mm.
  • the blood collection tube may have a wall thickness of about 2 mm to about 3 mm.
  • the blood collection tube may include an annular rim.
  • the annular rim may extend about .50 mm from the exterior wall of the tube.
  • the annular rim may extend about .25 to about .75 mm from the exterior wall of the tube.
  • the wall thickness may vary along the annular rim .
  • the wall thickness along the annular rim of the tube may be greater (e.g. about .25 mm to about .75 mm greater) than the wall thickness along the wall of the tube.
  • the blood sample collection tubes may be suitable for about 4 ml to about 10 ml of blood collection.
  • a small blood collection tube may be suitable for about 4 ml of blood sample collection.
  • a 4 ml blood collection tube may have a length as measured from the exterior of the base of the tube to the exterior of the stopper inserted at the open end of the tube of about 80 mm.
  • the blood collection tube may have a diameter as measured across the exterior wall of the inserted stopper of about 16 mm.
  • the outer diameter of the blood collection tube as measured at the coextensive elongated side wall adjacent base may be about 1 1 mm.
  • the outer diameter of the blood collection tube as measured at the coextensive elongated side wall adjacent the open end may be about 12 mm.
  • the inner diameter of the blood collection tube as measured at the coextensive elongated side wall adjacent the open end may be about 10 mm.
  • a large blood collection tube may be suitable for about 9 ml of blood sample collection.
  • a 9 ml blood collection tube may have a length as measured from the exterior of the base of the tube to the exterior of the stopper inserted at the open end of the tube of about 106 mm.
  • the blood collection tube may have a diameter as measured across the exterior wall of the inserted stopper of about 17 mm.
  • the outer diameter of the blood collection tube as measured at the coextensive elongated side wall adjacent the base may be about 13 mm.
  • the outer diameter of the blood collection tube as measured at the coextensive elongated side wall adjacent the open end may be about 15 mm.
  • the inner diameter of the tube as measured at the coextensive elongated side wall adjacent the open end may be about 13 mm.
  • the blood collection tube may include a reagent fill tolerance volume of about 54 ⁇ to about 66 ⁇ .
  • the blood collection tube may include a reagent fill tolerance volume of about 60 ⁇ .
  • the blood collection tube may include a reagent fill tolerance volume of about 162 ⁇ to about 198 ⁇ .
  • the blood collection tube may include a reagent fill tolerance volume of about 180 ⁇ .
  • the blood collection tube may include a reagent fill by weight of plus or minus 10% of 0.0708g.
  • the blood collection tube may include a reagent fill by weight of plus or minus 10% of 0.224g.
  • the blood collection tube may include a draw tolerance of about 3 ml to about 5 ml.
  • the blood collection tube may include a draw tolerance of about 4 ml.
  • the blood collection tube may include a draw tolerance of about 7 ml to about 13 ml.
  • the blood collection tube may include a draw tolerance of about 9 ml.
  • the blood collection tube may include a reagent fill volume of about 1 ml.
  • the blood collection tube may include a reagent fill volume of about 2 ml.
  • the blood collection tube may include a reagent fill volume of about 1 ml to about 2 ml.
  • a 10 ml blood collection tube may include a reagent fill volume of about 1 ml to about 2 ml.
  • a 4 ml blood collection tube may include a reagent fill volume of about 1 ml to about 2 ml.
  • the sample collection tube is a 4 ml blood collection tube.
  • the length of the tube may be about 75 mm.
  • the tube may have an average wall thickness along its length of about 1 .7 mm to about 2.2 mm.
  • the tube may have an average wall thickness along its length of about 2.0 mm.
  • the inner diameter of the tube as measured at the coextensive elongated side wall adjacent the open end may be about 10 mm.
  • the outer diameter of the tube as measured at the coextensive elongated side wall adjacent the open end may be about 12 mm.
  • the elongated side wall of the tube terminates at the open end in an annular rim that may be enlarged relative to the sidewalk
  • the inner wall of the annular rim may be curved.
  • the outer diameter of the tube as measured at the annular rim may be about 12 mm to about 14 mm.
  • the height of the annular rim may be about 1 .0 mm.
  • the tube may taper in diameter to a base.
  • the diameter of the base may be about 3 mm to about 4 mm.
  • the diameter of the base may be about 3.5 mm.
  • the base may include a recessed dimple.
  • the recess depth may be about .25 mm to about .75 mm.
  • the recess depth may be about .50 mm.
  • the sample collection tube is a 10 ml blood collection tube.
  • the length of the tube may be about 100 mm.
  • the tube may have an average wall thickness along its length of about 1 .7 mm to about 2.2 mm.
  • the tube may have an average wall thickness along its length of about 2.0 mm.
  • the inner diameter of the tube as measured at the coextensive elongated side wall adjacent the open end may be about 13 mm.
  • the outer diameter of the tube as measured at the coextensive elongated side wall adjacent the open end may be about 15 mm.
  • the elongated side wall of the tube terminates at the open end in an annular rim that may be enlarged relative to the sidewalk
  • the inner wall of the annular rim may be curved.
  • the outer diameter of the tube as measured at the annular rim may be about 15 mm to about 17 mm.
  • the height of the annular rim may be about 1 mm.
  • the tube may taper in diameter to a base.
  • the diameter of the base may be about 3 mm to about 4 mm.
  • the diameter of the base may be about 3.5 mm.
  • the base may include a recessed dimple.
  • the recess depth may be about .25 mm to about .75 mm.
  • the recess depth may be about .50 mm.
  • the polymeric material may be characterized as having one or more of the following: a moisture barrier and low moisture absorption rate, purity, transparency, chemical resistance, heat resistance and strength.
  • the polymeric material may have one or more of the following attributes: low density, high transparency, low birefringence, extremely low water absorption, excellent water vapor barrier properties, variable heat deflection properties, high rigidity, strength and hardness, very good blood compatibility, excellent biocompatibility, very good resistance to acids and alkalis, very good electrical insulating properties and very good processability/flowability.
  • the polymeric material may include a cyclic olefin.
  • the polymeric material may include cyclic olefin copolymer (COC).
  • the polymeric material may include cyclic olefin polymers (COP).
  • the polymeric material may include a homopolymer or copolymer that includes polyethylene, polypropylene or both.
  • the polymeric material may include a cyclic moiety.
  • the polymeric material may include a polyester.
  • the polymeric material may include polyester terephthalates or polyethylene terephthalate.
  • the polymeric material may include polycarbonates.
  • the polymeric material may include poly(methyl methacrylate).
  • the polymeric material may be processed in any suitable manner.
  • the polymeric material may be processed by methods for thermoplastics such as injection molding, extrusion, blow molding and injection blow molding.
  • the polymeric material may have excellent water vapor barrier properties.
  • the polymeric material may have a low moisture vapor transmission rate (MVTR) or water vapor transmission rate (VWTR).
  • the moisture vapor transmission rate may be determined according conventional testing methods such as DIN 53 122.
  • the polymeric material may have a moisture vapor transmission rate of about 0.023 g ⁇ mm/ m 2 ⁇ d to about 0.045 g ⁇ mm/ m 2 ⁇ d at 23 °C and 85% relative humidity, as measured by DIN 53 122.
  • the polymeric material may have a moisture vapor transmission rate of about 0.023 g ⁇ mm/ m 2 ⁇ d at 23 °C and 85% relative humidity.
  • the polymeric material may have a moisture vapor transmission rate of less than about 0.023 g ⁇ mm/ m 2 ⁇ d at 23 °C and 85% relative humidity.
  • the present teachings provide a blood collection tube which substantially prevents a reagent(s) from losing moisture over time. Moisture loss can cause the stabilizing reagent to become concentrated, which can potentially damage the integrity of all cells, including red blood cell lysis, producing excessive hemolysis.
  • the polymeric material may have high purity.
  • the polymeric material may have low extractables and leachables.
  • the polymeric material may be free of detectable residual metals.
  • the polymeric material may be free of one or more of the following: phthalates, bisphenol A, heavy metals, halogens, fluorochemicals or fluoropolymers and vinyl chloride polymer or monomer.
  • the polymeric material may allow for significant light transmission.
  • the light transmission may be determined by ISO 13468-2.
  • the polymeric material may have a light transmission of at least about 90%.
  • the polymeric material may have a light transmission of greater than 90%.
  • the polymeric material may have a relatively low birefringence.
  • the polymeric material may have a birefringence of about 1 nm to about 20 nm.
  • the polymeric material may have a birefringence of less than 20 nm according to ASTM D4093-95.
  • the polymeric material may have a birefringence of less than 15 nm according to ASTM D4093-95.
  • the polymeric material may have a birefringence of less than 10 nm according to ASTM D4093-95.
  • the polymeric material may have a birefringence of less than 5 nm according to ASTM D4093-95.
  • the polymeric material may have a birefringence of less than about 2 nm according to ASTM D4093-95.
  • the polymeric material may be chemically resistant.
  • the polymeric material may have very good resistance to acid and alkalis.
  • the polymeric material may be resistant to one or more of the following: methanol, ethanol, isopropanol, acetone and butanone.
  • the polymeric material may be thermally stable.
  • the coating may be thermally stable.
  • the polymeric material and coating may each have coefficients of thermal expansion that are within about twenty percent of each other.
  • the blood sample collection tube may be suitable for steam sterilization.
  • the blood sample collection tube may be suitable for gamma sterilization.
  • the polymeric material may be an amorphous substance.
  • the heat of fusion may be less than about 20 J/g.
  • the heat of fusion as measured by differential scanning calorimetry (DSC) may be less than about 10 J/g.
  • the heat of fusion as measured by differential scanning calorimetry (DSC) may be about less than 5 J/g.
  • the heat of fusion as measured by differential scanning calorimetry (DSC) may be less than about 2 J/g.
  • the polymeric material may have a glass transition temperature of about 78 °C to about 136 °C as measured by differential scanning calorimetry (DSC).
  • DSC differential scanning calorimetry
  • the storage temperature range of the sample collection tube is from about 16 °C to about 35 °C.
  • the storage humidity of the blood sample collection tube is about 22% to about 79% relative humidity (RH).
  • the polymeric material may have a relatively low mold shrinkage. Thus, it is possible to use the material to help avoid distortion of geometry upon removal from a mold.
  • the polymeric material may have a mold shrinkage of about 0.1 % to about 0.7%.
  • the polymeric material may have a mold shrinkage of less than about 0.1 %.
  • the polymeric material may have a high strength and rigidity.
  • the tensile strength and tensile modulus may be determined according to ISO 527 part 1 and 2.
  • the polymeric material may have a tensile strength of about 46 MPa to about 63 MPa, as measured by ISO 527, parts 1 and 2.
  • the polymeric material may have a tensile strength of about 60 MPa to about 63 MPa, as measured by ISO 527, parts 1 and 2.
  • the polymeric material may have a tensile modulus of about 2600 MPa to about 3200 MPa, as measured by ISO 527, parts 1 and 2.
  • the polymeric material may have a tensile modulus of about 2300 MPa to about 2600 MPa, as measured by ISO 527, parts 1 and 2.
  • the impact strength may be determined according to ISO 1791 ell.
  • the polymeric material may have an impact strength (Charpy Impact Unnotched) of about 13 kJ/m2 to about 20 kJ/m2, as measured by ISO 179/1 eU.
  • the polymeric material may have an impact strength (Charpy Impact Unnotched) of about 20 kJ/m2, as measured by ISO 179/1 eU.
  • the sample collection tube may include a coating.
  • the sample collection tube may be uncoated.
  • the sample collection tube may be a blood collection tube with a coating on the inner wall of the tube.
  • the coating may include one or more layers.
  • the coating may be generally transparent.
  • a layer of the coating may have a thickness of about 25 nm to about 1000 nm.
  • a layer of the coating may have a thickness of about 50 nm.
  • a layer of the coating may have a thickness of about 100 nm.
  • the coating may have an average thickness throughout the tube of about 100 nm to about 500 nm.
  • the coating may serve one or more functions.
  • the coating may contribute to the chemical stability of the polymeric blood collection tube.
  • the coating may contribute to the mechanical stability of the polymeric blood collection tube.
  • the coating of the blood collection tube may be such that it alters one or more characteristics of the interior surface of the blood collection tube.
  • the coating may alter the surface energy of the inner walls of the tube.
  • the coating may assist in preventing adherence of nucleic acids to the walls of the tube.
  • the coating may assist in retaining a stopper in the tube when exposed to variable air pressures such as those encountered during transport by air.
  • the coating may include multiple layers.
  • the coating may include one or more of the following layers: an adhesion layer, a barrier layer, a protective layer. Each layer may include different materials relative to an adjoining layer. Each layer may include the same or similar materials.
  • the coating may include a silicon containing material.
  • the coating may include silicon oxide or silica.
  • the coating may include one or more layers of silicon oxide.
  • the coating may be free of metal oxide additives.
  • the coating may include a first layer, a second layer and a third layer.
  • the first layer may be an adhesion layer deposited onto the inner wall of the polymeric sample collection tube.
  • the second layer may be a barrier layer deposited onto the inner wall of the tube on top of the adhesion layer.
  • the third layer may be a protective layer deposited onto the barrier layer.
  • the barrier layer may be in between the adhesion layer and the protective layer.
  • the coating may be deposited on the inner wall of the tube via any suitable mechanism.
  • the coating may be deposited onto the polymeric substrate by a plasma, a spray and/or a sputter deposition method. It may be applied by a vapor deposition method. It may be applied by a chemical deposition method. It may be applied by a physical deposition method. By way of one example, it may be applied by plasma enhanced chemical vapor deposition (PECVD).
  • PECVD plasma enhanced chemical vapor deposition
  • the coating including one or more layers is deposited onto the polymeric substrate by plasma deposition.
  • the plasma deposition method may be plasma-enhanced chemical vapor deposition.
  • the plasma process may utilize monomers and gases.
  • the plasma-enhanced chemical vapor deposition may include one or more of the following: an organosilicon precursor, oxygen, one or more noble gases.
  • the organosilicon precursor may include hexamethyldisiloxane (HMDSO), trimethylsilane (TriMS), tetramethylsilane (TetraMS), tetramethyldisiloxane (TMDSO), octamethylcyclotetrasiloxane (OMCTS) or a combination thereof.
  • the blood collection tube may be vacuum sealed in an enclosure.
  • the enclosure may include a gas inlet tube through which one or more gases and/or monomers are introduced into the enclosure.
  • a plasma may be established inside the blood collection tube by radio frequency energy excitation. The plasma may deposit a uniform coating onto the interior surface of the blood collection tube.
  • the polymeric material of the blood collection tube is such that it is compatible with an adhesive backed label.
  • the tube may include an adhesive-backed label adhered to an outer wall of the tube, and the adhesive may be an acrylic based adhesive.
  • the adhesive backed label may resist peeling from the outer wall of the tube and/or outer portion of the stopper.
  • the blood collection tube of the present teachings may include a reagent.
  • the tube may include a reagent with one or more ingredients.
  • the ratio of one or more ingredients of the reagent may be about 5:1 to about 15: 1 (e.g. 10:1 ).
  • the reagent may be solid.
  • the reagent may be substantially solid.
  • the reagent may be a liquid.
  • the reagent may be a gel.
  • the reagent may be a film.
  • the reagent may include an aqueous substance.
  • the reagent may include one or more agents in solution. Suitable solvents may include water, saline, dimethy!su!foxide, alcohol and any mixture thereof
  • the reagent may include a preservative.
  • the reagent may include an anticoagulant.
  • the reagent may include a preservative and an anticoagulant.
  • the tube may include a preservative and optionally an anticoagulant.
  • the reagent may include a preservative, an anticoagulant and one or more other agents.
  • the reagent may include one or more aldehyde reaction agents.
  • the aldehyde reaction agent may be selected from one or any combination of tris, glycine, or a derivative (e.g., a salt and/or an ester) of either or both.
  • the reagent may include one or more preservative agents, one or more enzyme inhibitors, one or more metabolic inhibitors, or any combination thereof.
  • the reagent may include glycine.
  • the blood collection tube may include the preservative imidazolidinyl urea (IDU), the anticoagulant EDTA and glycine.
  • the tube may include a reagent with one or more ingredients and a ratio of the one or more ingredients may be about 5: 1 to about 15: 1 .
  • the tube may include imidazolidinyl urea (IDU) and glycine and a ratio of imidazolidinyl urea (IDU) to glycine may be about 10:1 .
  • the aldehyde reaction agent may be present in a ratio (by weight) relative to the preservative composition of about 1 :20 to about 1 : 1 .
  • the aldehyde reaction agent may be present in a ratio (by weight) relative to the anticoagulant of about 1 :25 to about 5: 1 .
  • the preservative composition may be present in a ratio (by weight) relative to the anticoagulant of about 1 : 10 to about 15:1 .
  • the reagent may include one or more amines that may be selected from one or more of tryptophan, tyrosine, phenylalanine, glycine, ornithine and S- adenosylmethionine, aspartate, glutamine, alanine, arginine, cysteine, glutamic acid, glutamine, histidine, leucine, lysine, proline, serine, threonine, or combinations thereof.
  • the one or more amines may be chosen based upon their reactive capabilities. As one non-limiting example, it is possible that the one or more amines be aldehyde reaction agents.
  • the aldehyde reaction agent may be selected from one or any combination of tris, lysine, glycine, urea, or a derivative (e.g., a salt and/or an ester) of either or both.
  • the aldehyde reaction agent may be selected to react with any free formaldehyde that may be present either prior to or post sample collection.
  • the concentration of the amines in the reagent may be from about 0.25% to about 1 .5%.
  • the concentration of the one or more amines may be from about 0.3% to about 0.8%.
  • the concentration of the one or more amines may be about 0.4% to about 0.7%.
  • the reagent may include one or more anticoagulants or chelating agents which may be selected from the group consisting of ethylene diamine tetra acetic acid (EDTA) and its salts, ethylene glycol tetra acetic acid (EGTA) and its salts, hirudin, heparin, citric acid, salts of citric acid, oxalic acid, salts of oxalic acid, acid citrate dextrose (ACD), citrate, citrate-theophylline-adenosine-dipuridamole (CTAD), citrate- pyridoxalphosphate-tris, heparin-p-hydroxy-ethyl-theophylline, polyanethol sulfonate, sodium fluoride, sodium heparin, thrombin and PPACK (D-phenylalanyl-L-prolyl-L- arginine chloromethyl ketone and any combination thereof.
  • EDTA ethylene diamine te
  • the concentration of the anticoagulant in the reagent may be from about 2.5% to about 10%.
  • the concentration of the anticoagulants may be from about 3% to about 8%.
  • the concentration of the anticoagulants may be about 4% to about 7%.
  • the reagent may include one or more polysaccharides, which may be selected from starch, cellulose, glycogen, or combinations thereof.
  • the one or more polysaccharides may act as erythrocyte protectant agents.
  • the one or more polysaccharides may assist in stabilizing erythrocyte membranes, such that cell lysis is slowed, minimized, substantially prevented or some combination thereof.
  • the concentration of the polysaccharides in the reagent may be from about 0.001 % to about 5.0%.
  • the concentration of the polysaccharides in the reagent may be from about 0.02% to about 3.0%.
  • the concentration may be about 0.5% to about 2.0%.
  • the reagent may include one or more transcription inhibitors, which may be selected to promote stability of one or more components within a sample.
  • the one or more transcription inhibitors may be selected from actinomycin D, a-amanitin, triptolide, 5,6-dichloro-1 -p-D-ribofuranosylbenzimidazole (DRB), flavopiridol, or any combination thereof.
  • the concentration of the one or more transcription inhibitors may be about 0.5 ⁇ to about 500 ⁇ .
  • the reagent may include one or more enzyme inhibitors.
  • the one or more enzyme inhibitors may be selected from the group consisting of: diethyl pyrocarbonate, ethanol, aurintricarboxylic acid (ATA), glyceraldehydes, sodium fluoride, ethylenediamine tetraacetic acid (EDTA), formamide, vanadyl-ribonucleoside complexes, macaloid, heparin, hydroxylamine-oxygen-cupric ion, bentonite, ammonium sulfate, dithiothreitol (DTT), beta-mercaptoethanol, cysteine, dithioerythritol, tris(2-carboxyethyl)phosphene hydrochloride, a divalent cation such as Mg+2, Mn+2, Zn+2, Fe+2, Ca+2, Cu+2 and any combination thereof.
  • ATA aurintricarboxylic acid
  • EDTA
  • the reagent may include one or more metabolic inhibitors.
  • the one or more metabolic inhibitors may be selected from the group consisting of: glyceraldehyde, dihydroxyacetone phosphate, glyceraldehyde 3-phosphate, 1 ,3-bisphosphoglycerate, 3- phosphoglycerate, 2-phosphoglycerate, phosphoenolpyruvate, pyruvate and glycerate dihydroxyacetate, sodium fluoride, K2C2O4 and any combination thereof.
  • the reagent may include one or more protease inhibitors.
  • the one or more protease inhibitors may be selected from the group consisting of: antipain, aprotinin, chymostatin, elastatinal, phenylmethylsulfonyl fluoride (PMSF), APMSF, TLCK, TPCK, leupeptin, soybean trypsin inhibitor, indoleacetic acid (IAA), E-64, pepstatin, VdLPFFVdL, EDTA, 1 ,10-phenanthroline, phosphoramodon, amastatin, bestatin, diprotin A, diprotin B, alpha-2-macroglobulin, lima bean trypsin inhibitor, pancreatic protease inhibitor, egg white ovostatin egg white cystatin, and any combination thereof.
  • the protective agent may include a phosphatase inhibitor selected from the group consisting of: calyculin A, nodularin, NIPP-1 , microcystin LR, tautomycin, okadaic acid, cantharidin, microcystin LR, okadaic acid, fostriecin, tautomycin, cantharidin, endothall, nodularin, cyclosporin A, FK 506/immunophilin complexes, cypermethrin, deltamethrin, fenvalerate, bpV(phen), dephostatin, mpV(pic) DMHV, sodium orthovanadate and any combination thereof.
  • a phosphatase inhibitor selected from the group consisting of: calyculin A, nodularin, NIPP-1 , microcystin LR, tautomycin, okadaic acid, cantharidin, microcystin LR,
  • the reagent may include one or more nuclease inhibitors.
  • the one or more nuclease inhibitors may be selected from the group consisting of: diethyl pyrocarbonate, ethanol, aurintricarboxylic acid (ATA), formamide, vanadyl-ribonucleoside complexes, macaloid, ethylenediamine tetraacetic acid (EDTA), proteinase K, heparin, hydroxylamine-oxygen-cupric ion, bentonite, ammonium sulfate, dithiothreitol (DTT), beta-mercaptoethanol, cysteine, dithioerythritol, tris(2-carboxyethyl) phosphene hydrochloride, or a divalent cation such as Mg+2, Mn+2, Zn+2, Fe+2, Ca+2, Cu+2 and any combination thereof.
  • the reagent may include one or more phosphatase inhibitors.
  • the one or more phosphatase inhibitors may be selected from the group consisting of: calyculin A, nodularin, NIPP-1 , microcystin LR, tautomycin, okadaic acid, cantharidin, imidazole, microcystin LR, okadaic acid, fostriecin, tautomycin, cantharidin, endothall, nodularin, cyclosporin A, FK 506/immunophilin complexes, cypermethrin, deltamethrin, fenvalerate, bpV(phen), dephostatin, mpV(pic) DMHV, sodium orthovanadate and any combinations thereof.
  • the reagent may include bicyclic oxazolidines, DMDM hydantoin, sodium hydroxymethylglycinate, hexamethylenetetramine chloroallyl chloride, biocides, a water- soluble zinc salt or any combination thereof.
  • the reagent may include a polyacrylic acid or a suitable acid having a pH ranging from about one to about seven.
  • the reagent may include amines, amino acids, alkyl amines, polyamines, primary amines, secondary amines, ammonium salts, or any combination thereof.
  • the reagent may include one or more primary amines.
  • the reagent may include one or more amides (e.g. butanamide).
  • the reagent may include one more apoptosis inhibitors.
  • the reagent may include one or more caspase inhibitors.
  • the reagent may include one or more polymer ingredients.
  • the polymers may include but are not limited to the following: polyvinylpyrrolidone (PVP), polyethylene glycol (PEG) and cyclodextrin.
  • the reagents described herein may also include additional components, including one or more of the following: Doxycycline, Polyethylene Glycol, Sulfasalazine, Polyvinylpyrrolidone, Curcumin, Magnesium Gluconate, Homocysteine, Methyl Cellulose (MC), 6-Aminocaproic acid, Ethyl Cellulose, Aprotinin, Hydroxyethyl Cellulose, Doxycycline, Hydroxypropyl Cellulose, Minocycline HCI, Dextrin, Nicotinamide, Dextran, Chitosan, Polyethylene Oxide, Lysine, Poly Ethyl Oxazoline, Glyceraldehyde, Ficolls, Phytic Acid, a-Cyclodextrin, b-Sitoserol, ⁇ -Cyclodextrin, C-AMP, Y-Cyclodextrin, Poly Lysine, Gelatins, Biochan
  • the reagents may include one or more cell permeabilizing agents.
  • the one or more cell permeabilizing agents may be selected from the group consisting of: DMSO (dimethyl sulfoxide), ethylene glycol, polyethylene glycol, glycerin, Cellosolves (ethylene glycol dimethyl ether) (phenoxyethanol), Triton X 100, Triton X 705 (non-ionic detergents), 1 -methyl-2-pyrrolidinone, Tween 20, Tween 40 (non-ionic), Brij 35 (detergent), polyoxyethylene ether (Polyox), sodium cholate, ethylene oxide polymers, monensin, monactin, pentachlorophenol, 2,4 dinitrophenol, saponin, SDS (sodium dodecyl sulfate) and combinations thereof.
  • the reagent may include proteins such as: biotin, albumins (egg, bovine), gelatin, and similar such compounds.
  • the reagent may include RNAse inhibitors such as: human placenta derived RNAse inhibitor, and similar such compounds.
  • the reagent may include nucleic acid stabilizers such as: guanidinium hydrochloride, polycations such as polyethylenimine, and similar such compounds.
  • the reagent may include amino acids/polypeptides such as: glutamic acid, glycine, aspartic acid, and similar such compounds.
  • the reagent may include fixatives such as: aldehydes (formaldehyde and glutaraldehyde), alcohols (ethanol, methanol), and similar such compounds.
  • the reagent may include anticoagulants such as: EDTA (Ethylene Diamine Tetra acetic acid), and similar such compounds.
  • the reagent may include ACD (Acid Citrate Dextrose), Heparin, and similar such compounds.
  • the reagent may include protease inhibitors such as: EDTA, PMSF (phenyl methyl sulfonyl fluoride), AEBSF (2-Aminoethyl benzene sulfonyl fluoride), and similar such compounds.
  • the reagent may include antioxidants/reducing agents such as: Trolox, a-tocopherol, B-mercaptoethanol, and similar such compounds.
  • the reagent may include nucleic acid dyes such as: DAPI (diamidino 2-phenylindole), propidium iodide, fluorescein diacetate, and similar such compounds.
  • the reagent may include carbohydrates such as: sugars (sucrose), cellulose, and similar such compounds. It should be appreciated that the above specific listings of compounds may contain a measure of overlap, which recognizes the sometimes-overlapping function of certain specific compounds. One of skill in the art should understand and appreciate this aspect of the disclosure.
  • the reagent may be present in the tube as a liquid in an amount less than about 10% by volume of the tube but greater than about 0.1 % by volume.
  • the reagent may be present in the tube as a liquid in an amount less than about 5% by volume of the tube but greater than about 0.1 % by volume of the tube.
  • the reagent may be present in the tube in an amount less than about 3% by volume of the tube but greater than about 0.1 % by volume of the tube. It is possible that at any point in time (e.g., prior to blood draw, just following blood draw, 1 hour post blood draw, 12 hours post blood draw, 4 days post blood draw) the tube may contain a detectable amount of formaldehyde.
  • the tube contains blood plasma, a preservative, an anticoagulant, and formaldehyde. It is further possible that the tube contain blood plasma, a preservative, an anticoagulant, formaldehyde, and a plurality of cell-free nucleic acids (e.g., cell-free DNA (which may be cell-free fetal DNA, cell free RNA (which may be cell-free mRNA), circulating tumor- derived nucleic acids, or nucleic acids of other origin).
  • cell-free DNA which may be cell-free fetal DNA
  • cell free RNA which may be cell-free mRNA
  • circulating tumor- derived nucleic acids or nucleic acids of other origin.
  • the blood collection tube of may include a blood draw volume of about 4 ml to about 10 ml.
  • the blood collection tube may include a reagent volume of about .20 ml to about .90 ml.
  • the blood collection tube may include about .20 ml to about .30 ml of reagent for a blood draw volume of about 8 ml to about 10 ml.
  • the blood collection tube may include about .60 ml to about .90 ml of reagent for a blood draw volume of about 4 ml to about 6 ml.
  • the reagent in the tube may include about 15% to about 70% by volume of the preservative composition prior to blood draw.
  • the reagent in the tube may include about 15% to about 70% by volume of imidazolidinyl urea (IDU) prior to blood draw.
  • the reagent in the tube include may include about 5% to about 20% by volume of anticoagulant prior to blood draw.
  • the reagent in the tube may include about 5% to about 20% of anticoagulant prior to blood draw.
  • the reagent in the tube may include about 5% to about 10% of anticoagulant prior to blood draw.
  • the reagent in the tube may include about 1 % to about 10% of an agent in addition to the preservative and an anticoagulant prior to blood draw.
  • the reagent may include one or more preservative agents.
  • the preservative may be selected from the group consisting of formaldehyde, diazolidinyl urea (DU), imidazolidinyl urea (IDU), dimethylol urea, 2-bromo-2-nitropropane-1 ,3-diol, 5- hydroxymethoxymethyl-1 -aza-3,7-dioxabicyclo (3.3.0)octane and 5-hydroxymethyl-1 - aza-3,7-dioxabicyclo (3.3.0)octane and 5-hydroxypoly [methyleneoxy]methyl-1 -aza-3,7- dioxabicyclo (3.3.0)octane, bicyclic oxazolidines, DMDM hydantoin, sodium hydroxymethylglycinate, hexamethylenetetramine chloroallyl chloride, biocides, a water- soluble zinc salt and any combination thereof.
  • the one or more preservative agents may include a formaldehyde releaser such as one selected from the group consisting of: diazolidinyl urea, imidazolidinyl urea, dimethoylol-5,5-dimethylhydantoin, dimethylol urea, 2-bromo-2.-nitropropane-1 ,3-diol, oxazolidines, sodium hydroxymethyl glycinate, 5- hydroxymethoxymethyl-1 -1 aza-3,7-dioxabicyclo [3.3.0]octane, 5-hydroxymethyl-1 -1 aza- 3,7dioxabicyclo[3.3.0]octane, 5-hydroxypoly[methyleneoxy]methyl-1 -1 aza-
  • a formaldehyde releaser such as one selected from the group consisting of: diazolidinyl urea, imidazolidinyl urea, dimethoylol-5,5-d
  • the reagent may contain less than about 20 parts per million (ppm) of an aldehyde per 100 ⁇ of the reagent (prior to contact with a sample).
  • the reagent may contain less than about 15 parts per million (ppm) of an aldehyde per 100 ⁇ of the reagent.
  • the reagent may contain less than about 10 parts per million (ppm) of an aldehyde per 100 ⁇ of the reagent.
  • the reagent may contain less than about 5 parts per million (ppm) of an aldehyde per 100 ⁇ of the reagent.
  • the reagent may contain at least about 0.1 parts per million (ppm) per 100 ⁇ of the reagent.
  • the reagent may contain at least about 0.5 parts per million (ppm) to about 15 ppm of an aldehyde per 100 ⁇ of the reagent.
  • the reagent may contain at least about 1 part per million (ppm) of an aldehyde per 100 ⁇ of the reagent.
  • the reagent may contain at least about 10 parts per million (ppm) of an aldehyde per 100 ⁇ of the reagent.
  • the reagent may contain at least about 100 parts per million (ppm) of an aldehyde per 100 ⁇ of the reagent.
  • the reagent may contain at least about 1000 parts per million (ppm) of an aldehyde per 100 ⁇ of the reagent.
  • the reagent may contain at least about 10,000 parts per million (ppm) of an aldehyde per 100 ⁇ of the reagent.
  • the reagent may contain less than 1 parts per million (ppm) an aldehyde per 100 ⁇ of the reagent after contact with a sample.
  • the aldehyde may include formaldehyde.
  • the reagent may include one or more aldehyde reaction agents.
  • the reagent may include an amount of aldehyde reaction agent containing a primary amine for reacting with free formaldehyde present in the reagent to result in an aldehyde amount below 10,000 ppm per 100 ⁇ of reagent prior to blood draw.
  • the reagent may include an amount of aldehyde reaction agent, which aldehyde reaction agent is selected from one or any combination of tris, glycine, or a derivative (e.g., a salt and/or an ester) of either or both, for reacting with free formaldehyde present in the reagent to result in an aldehyde amount below 10,000 ppm per 100 ⁇ of reagent prior to blood draw.
  • aldehyde reaction agent is selected from one or any combination of tris, glycine, or a derivative (e.g., a salt and/or an ester) of either or both, for reacting with free formaldehyde present in the reagent to result in an aldehyde amount below 10,000 ppm per 100 ⁇ of reagent prior to blood draw.
  • ingredients may be employed in the sample collection tube disclosed herein, as desired, to achieve the desired resulting characteristics.
  • examples of other ingredients that may be employed include antibiotics, anesthetics, antihistamines, preservatives, surfactants, antioxidants, unconjugated bile acids, mold inhibitors, nucleic acids, pH adjusters, osmolarity adjusters, or any combination thereof.
  • the blood collection tube may be non-reactive to one or more ingredients.
  • the blood collection tube may be non-reactive to anticoagulants.
  • the blood collection tube may be non-reactive to preservatives.
  • the blood collection tube may be non-reactive to the collected blood sample.
  • the blood collection tube may be non- reactive to the combination of the one or more ingredients and the collected blood sample.
  • the reagent may include or the tube may be adapted to receive one or more materials for enabling isolation of a cellular or cell-free component of a blood sample. Such materials may include a protease or amino acid which may include but is not limited to proteinase K.
  • the tube may be suitable for storing a blood sample for a period of at least about 7 days.
  • the tube may be suitable for storing a blood sample for a period of at least about 14 days.
  • the tube may be suitable for storing a blood sample for a period of at least about 30 days.
  • the tube may be suitable for storing a blood sample for a period of at least about 60 days.
  • the tube may be suitable for storing a blood sample for a period of at least about 90 days.
  • a blood sample stored in the blood collection tube of the present teachings will result in a substantial increase in the amount of recoverable nucleic acid from the blood sample (as compared to a sample collected in a standard tube and/or a polymeric tube with no coating).
  • a blood sample stored in the tube having a silicon containing coating may result in a substantial increase in the amount of recoverable nucleic acid or rare cells as compared with a polymeric tube of the same polymer but with no coating and the substantial increase may be at least about 10%.
  • a blood sample stored in the tube having a silicon-containing coating may result in a substantial increase in the amount of recoverable nucleic acid or rare cells as compared with a polymeric tube of the same polymer but with no coating and the substantial increase may be at least about 20%.
  • a blood sample stored in the tube having a silicon-containing coating may result in a substantial increase in the amount of recoverable nucleic acid or rare cells as compared with a polymeric tube with no coating and the substantial increase may be at least about 30%.
  • FIG.1 depicts an illustrative example of the blood collection tube assembly 300 of the present teachings.
  • the blood collection tube 100 is cylindrical in shape.
  • the tube 100 includes a stopper 200 inserted in the opening 20 of the tube 100.
  • FIGS. 2(a)-(c) depict an illustrative example of a 4 ml blood collection tube.
  • the tube 100 includes an opening 20.
  • the opening 20 of the tube 100 includes an annular rim 30.
  • the tube 100 includes a base portion 40 opposing the opening 20.
  • the tube 100 tapers in diameter to the base 40.
  • the base 40 includes a recessed dimple 50.
  • FIG. 2(b) illustrates a close-up view of portion B of the tube 100 of FIG. 2(a) depicting the upper portion of the tube 100 terminating at an open end and including an annular rim 30.
  • the annular rim 30 is enlarged relative to the coextensive sidewall of the tube 100.
  • FIG. 2(c) illustrates a close-up view of portion C of the tube 100 of FIG. 2(a) depicting the lower portion of the tube 100 including a base 40 and recessed dimple 50.
  • FIGS. 3(a)-(c) depict an illustrative example of a 10 ml blood collection tube.
  • the tube 100 includes an opening 20.
  • the opening 20 of the tube 100 includes an annular rim 30.
  • the tube 100 includes a base portion 40 opposing the opening 20.
  • the tube 100 tapers in diameter to the base 40.
  • the base 40 includes a recessed dimple 50.
  • FIG. 3(b) illustrates a close-up view of portion B of the tube 100 of FIG. 3(a) depicting the upper portion of the tube 100 terminating at an open end and including an annular rim 30.
  • the annular rim 30 is enlarged relative to the coextensive sidewall of the tube 100.
  • FIG. 3(c) illustrates a close-up view of portion C of the tube 100 of FIG. 3(a) depicting the lower portion of the tube 100 including a base 40 and recessed dimple 50.
  • FIG. 4(a) depicts the results of draw volume verification for twenty 9 ml blood collection tubes of the present teachings.
  • the water draw volume was within 9 ml_ ⁇ 10% for each tube.
  • the water draw volume was to be within 9 ml_ ⁇ 10% for each tube in accordance with ISO 6710.
  • the results demonstrate that the water draw volume of each polymeric coated tubes including reagent was within the specification, as shown in FIG. 4(a), with an average of 9.45 mL (StDev: 0.018 mL). (The tubes are manufactured such that the minimum volume for a properly drawn sample at the beginning of product dating is 9.0 mL.)
  • FIG. 4(b) depicts the results of draw volume verification for twenty 4 ml blood collection tubes of the present teachings.
  • the water draw volume was within 4 mL ⁇ 10% for each tube.
  • the water draw volume was to be within 4 mL ⁇ 10% for each tube in accordance with ISO 6710.
  • the results demonstrate that the water draw volume of each polymeric coated tubes including reagent was within the specification, as shown in FIG. 4(b), with an average of 3.959 mL (StDev: 0.028 mL). (The tubes are manufactured such that the minimum volume for a properly drawn sample at the beginning of product dating is 4.0 mL.)
  • the present teachings demonstrate there is no statistically significant difference between plasma recovery from glass blood collection tubes and the blood collection tubes of the present teachings.
  • Plasma recovery was tested utilizing 10 mL glass blood collection tubes and 9 mL blood collection tubes of the present teachings.
  • whole blood was centrifuged at 300 x g for 20 minutes at room temperature to separate plasma.
  • the plasma recovery was 4.5 mL for a 10 mL glass tube and 4.1 mL for a 9.0 mL blood collection tube of the present teachings ( ⁇ 10% difference).
  • whole blood was centrifuged at 1 ,600 x g for 10 minutes at room temperature to separate plasma.
  • the plasma recovery was 5.5 mL for a 10 mL glass tube and 5.0 mL for a 9.0 mL blood collection tube of the present teachings ( ⁇ 10% difference). (The blood collection tubes of the present teachings will see approximately 10% less plasma due to the draw volume difference from 10 mL to 9 mL.)
  • FIGS. 5-7 depict cell-free DNA genome equivalents per 1 mL of plasma for a storage temperature study assessing glass blood collection tubes and the blood collection tubes of the present teachings.
  • FIG. 8 depicts cell-free DNA genome equivalents per 1 ml_ of plasma for a shipping and handling study assessing glass blood collection tubes and the blood collection tubes of the present teachings.
  • the present teachings demonstrate there is no statistically significant difference between the performance (i.e., stabilization attributes) of a cell-free nucleic acid reagent, such as that utilized in Cell-Free DNA BCT® by Streck (Omaha, Iowa), in glass evacuated blood collection tubes and the evacuated blood collection tubes of the present teachings as it relates to cellular DNA contamination of cell-free DNA (cfDNA) in plasma during whole blood sample storage, shipping and handling.
  • a cell-free nucleic acid reagent such as that utilized in Cell-Free DNA BCT® by Streck (Omaha, Iowa
  • the blood plasma separation process included a 2-step process. First, blood was mixed and centrifuged in each blood collection tube at 18-25 °C at an initial low speed centrifugation at 300 x g for 20 minutes. Second, the plasma layer was carefully removed without disturbing the buffy coat, transferred to a new vial, and centrifuged at 18-25 °C at 5,000 x g for 10 minutes to remove residual cells. Plasma was stored at -80 °C until cell-free DNA isolation or processed immediately. This process was performed at each testing interval for both the storage temperature and shipping and handling studies.
  • Cell-free DNA was isolated from plasma. Extraction of cell-free DNA can be accomplished using most commercially available kits. Specific to this evaluation, the QIAamp® Circulating Nucleic Acid Kit (Qiagen, Santa Clarita, CA) was used for extraction of cell-free DNA from the plasma complement. The manufacturer's recommended protocol was modified to increase the duration of the Proteinase K treatment from 30 minutes to 1 hour at 60 °C per the instructions for use protocol. Isolated cfDNA was stored at -80 °C until analysis by Droplet Digital Polymerase Chain Reaction (ddPCR).
  • ddPCR Droplet Digital Polymerase Chain Reaction
  • Final concentrations of primers and probe in PCR reactions were 900 nM and 250 nM, respectively, in a final volume of 20 ⁇ .
  • a Bio-Rad QX100 Droplet DigitalTM PCR System was used. Thermal cycling was performed with a Bio-Rad C1000 Touch Thermal Cycler. The following PCR conditions were used: 10 minutes at 98 °C; 40 cycles of 30 seconds at 95 °C, 30 seconds at 54 °C, and 30 seconds at 72 °C. A final extension of 10 min at 72 °C was followed by a heating step for 10 minutes at 98 °C to inactivate the polymerase. Data analysis was performed using Bio-Rad QuantaSoft software version 1 .3.2.
  • GE/mL Genome Equivalent/mL of Plasma
  • the present teachings demonstrate there is no statistically significant difference between the performance of a cell-free nucleic acid reagent, such as that utilized in Cell-Free DNA BCT® by Streck (Omaha, Iowa), in glass evacuated blood collection tubes and the evacuated blood collection tubes of the present teachings as it relates to the stabilization of circulating tumor cells (CTC) during whole blood sample storage at 15-30 °C.
  • CTC circulating tumor cells
  • the effective stabilization of CTCs with blood drawn into glass Cell- Free DNA BCT® has been shown. (Qin et al. Stabilization of circulating tumor cells in blood using a collection device with a preservative reagent. Cancer Cell International 2014, 14:23.)
  • Table 1 Mean CTC recovery at day 7 for polymeric coated tube with reagent.
  • the present teachings demonstrate there is no statistically significant difference between the performance (i.e., stabilization attributes) of a immunophenotyping preservative reagent, such as that utilized in Cyto-Chex BCT® by Streck (Omaha, Iowa), in glass evacuated blood collection tubes and the evacuated blood collection tubes of the present teachings as it relates to immunophenotyping of white blood cells during whole blood sample storage, shipping and handling.
  • a immunophenotyping preservative reagent such as that utilized in Cyto-Chex BCT® by Streck (Omaha, Iowa
  • the glass tube and the blood collection tube of the present teachings stored at 37 °C were tested 48 hours post blood draw for CD8. The same two tubes were tested 72 hours post blood draw for CD3 and CD4.
  • the glass tube and the blood collection tube of the present teachings stored at 30 °C were tested 7 days post blood draw for the HIV panel of markers (CD3, CD4, CD8, CD19, CD16/56, and CD45).
  • the glass tube and the blood collection tube of the present teachings stored at 18 °C to 22 °C were tested 7 days and 14 days post blood draw for the HIV panel of markers (CD3, CD4, CD8, CD19, CD16/56, and CD45).
  • the acceptance criteria is as follows: the % difference of CD marker recovery between EDTA tubes and the blood collection tubes of the present teachings must be ⁇ 20% for all studies and testing conditions.
  • the HIV panel of markers including CD3, CD4, CD8, CD16/56, CD19 and CD45 are stable in blood samples stored in the blood collection tubes of the present teachings for up to 14 days at 18 °C to 22 °C and up to 7 days at 30 °C.
  • CD8 is stable for up to 48 hours at 37 °C.
  • CD3 and CD4 are stable for up to 72 hours at 37 °C.
  • Immunophenotypic analysis performed on peripheral blood samples stored in the blood collection tubes of the present teachings provides the same results as when performed on fresh specimens as shown in Tables 2-10.
  • Table 2 Percent difference of cell count recovery between day 7 glass tube with immunophenotyping preservative reagent, polymeric coated tube with immunophenotyping preservative reagent and initial EDTA for storage temperature study at 18 °C to 22 °C.
  • Table 3 Percent difference of cell count recovery between day 14 glass tube with immunophenotyping preservative reagent, polymeric coated tube with immunophenotyping preservative reagent and initial EDTA for storage temperature study at 18 °C to 22 °C.
  • CD8 12 329 309 6.1% 289 12.3% CD16/CD56 12 238 212 11.0% 227 4.6% CD19 12 127 133 4.3% 119 6.2% CD45 12 1522 1507 1.0% 1489 2.2%
  • Table 4 Percent difference of cell count recovery between day 7 glass tube with immunophenotyping preservative reagent, polymeric coated tube with immunophenotyping preservative reagent and initial EDTA for storage temperature study at 30 °C.
  • Table 5 Percent difference of cell count recovery between 48-hour glass tube with immunophenotyping preservative reagent, polymeric coated tube with immunophenotyping preservative reagent and initial EDTA for storage temperature study at 37 °C.
  • Table 7 Percent difference of cell count recovery between day 7 glass tube with immunophenotyping preservative reagent, polymeric coated tube with immunophenotyping preservative reagent and initial EDTA for shipping and handling study of non-shipped tubes.
  • Table 8 Percent difference of cell count recovery between day 14 glass tube with immunophenotyping preservative reagent, polymeric coated tube with immunophenotyping preservative reagent and initial EDTA for shipping and handling study of non-shipped tubes.
  • Table 9 Percent difference of cell count recovery between day 7 glass tube with immunophenotyping preservative reagent, polymeric coated tube with immunophenotyping preservative reagent and initial EDTA for shipping and handling study of shipped tubes.
  • Table 10 Percent difference of cell count recovery between day 14 glass tube with immunophenotyping preservative reagent, polymeric coated tube with immunophenotyping preservative reagent and initial EDTA for shipping and handling study of shipped tubes.
  • FIG. 9(a) illustrates that the 9 ml blood collection tubes of the present teachings have an oxygen transmission rate 6 times lower than PET (polyethylene terephthalate) tubes.
  • FIG. 9(b) illustrates that the 4 ml blood collection tubes of the present teachings have an oxygen transmission rate 5 times lower than PET (polyethylene terephthalate) tubes.
  • FIG. 10(a) depicts the theoretical draw volume over product dating of the 9 ml blood collection tubes of the present teachings vs. PET tubes. There is a 6.3% loss compared to a 37.1 % loss in draw volume over 24 months.
  • FIG. 10(b) depicts the theoretical draw volume over product dating of the 4 ml blood collection tubes of the present teachings vs. PET tubes. There is a 9.8% loss compared to a 50.1 % loss in draw volume over 24 months.
  • Moisture transmission testing was performed on PET tubes and blood collection tubes of the present teachings over 28 days at 18-25 °C, 30 ⁇ 2 °C, and 50 ⁇ 2 °C. These tests were performed to demonstrate that the blood collection tubes of the present teachings do not allow the stabilizing reagent to lose moisture over time. Moisture loss can cause the stabilizing reagent to become concentrated, which can produce excessive hemolysis. The 28-day moisture transmission study for all three temperature conditions demonstrates that the blood collection tubes of the present teachings do not allow the stabilizing reagent to lose significant moisture over time. Moisture loss (mg) over 28 days for the blood collection tubes of the present teachings vs. PET is displayed in FIG. 1 1 .
  • results of a comparative analysis moisture vapor barrier study over 85 days at 22 °C, 30 °C and 50 °C of commercial plastic blood collection tubes and blood collection tubes of the present teachings are depicted in FIG. 12.
  • the initial reagent fill volume is 200 ⁇ _ for the blood collection tube of the present teachings, 300 ⁇ _ for plastic blood collection tube # 1 and 1500 ⁇ _ for plastic blood collection tube # 2.
  • the blood collection tube of the present teachings had a reported loss of 1 .3 ⁇ _ (« 0.65%)
  • plastic blood collection tube # 1 had a reported loss of 41 .5 ⁇ _ (« 13.8%)
  • plastic blood collection tube # 1 had a reported loss of 45.6 ⁇ _ ( « 3.0%).
  • the blood collection tube of the present teachings had a reported loss of 7.1 ⁇ _ (« 3.6%), plastic blood collection tube # 1 had a reported loss of 166.2 ⁇ _ ( ⁇ 55.4%) and plastic blood collection tube # 2 had a reported loss of 207.5 ⁇ _ ( ⁇ 13.8%).
  • the blood collection tube of the present teachings had a reported loss of 31 .3 ⁇ _ ( ⁇ 15.7%), plastic blood collection tube # 1 had a reported loss of 298 ⁇ _ (« 99.3%) and plastic blood collection tube # 2 had a reported loss of 641 ⁇ _ ( ⁇ 42.7%).
  • the 85 day comparative analysis moisture vapor barrier study for all three temperature conditions demonstrates that the blood collection tubes of the present teachings do not allow the stabilizing reagent to lose significant moisture over time as compared to commercial plastic blood collection tubes.
  • test samples were exposed to the 95 kPa pressure differential for at least 30 minutes.
  • the pressure inside the vacuum chamber was slowly increased to ambient air pressure, then the vacuum chamber was opened.
  • the corrugated board holder was removed from the vacuum chamber, and each test sample was subjected to a visual inspection for leaks or any signs of damage (cracks, crazing, etc.).
  • sample collection tubes of the present teachings provide blood collect tubes which are compliant with established FDA standards. Therefore, the present teachings provide sample collection tubes in which collected samples may be shipped by air for testing and analysis.
  • ISTA 1 A testing applies to packaged products weighing 150 lbs. or less and challenges the capability of the package and product to withstand transport hazards.
  • ISTA 1A testing was performed on 12 twelve blood collection tubes of the present teachings. Acceptance criteria was a passing result for ISTA 1A (shock drop and fixed displacement vibration) testing. No physical issues were observed when the twelve blood collection tubes of the present teachings were subjected to ISTA 1 A (shock drop and fixed displacement vibration) testing.
  • the sample collection tube is a 4.0 ml blood collection tube.
  • the blood collection tube is about 13mm x 75mm.
  • the fill tolerance volume is about
  • the fill by weight is about 0.0708g +/- 10%
  • the draw tolerance is about 4ml and may range from about
  • the vacuum expiration date is 24 months from the date of manufacture.
  • the sample collection tube is a 10.0 ml blood collection tube for cell-free nucleic acid analysis.
  • the blood collection tube is about 16mm x 100 mm.
  • the fill tolerance volume is about 200.0 ⁇ +/- 10% (180 ⁇ to 220 ⁇ /tube).
  • the fill by weight is about 0.249g +/- 10% (0.2241 g to 0.2739g/tube).
  • the draw tolerance is about 10 ml and may range from about 9.0 ml to about 1 1 .0 ml.
  • the vacuum expiration date is 24 months from the date of manufacture.
  • An exemplary sample collection tube may be a 9.0 ml blood collection tube.
  • the blood collection tube is about 16mm X 100 mm.
  • the fill tolerance volume is about 180.0 ⁇ +/- 10% (162 ⁇ to about 198 ⁇ ).
  • the fill by weight is about 0.2241 g +/- 10% (0.2017g to 0.2564g/tube).
  • the draw tolerance is about 9 ml and may range from +/- 10% (e.g. 8.1 ml to 9.9 ml).
  • the draw height may be about 80mm to about 84 mm.
  • the vacuum expiration date is 24 months from the date of manufacture.
  • any member of a genus may be excluded from the genus; and/or any member of a Markush grouping may be excluded from the grouping.
  • any numerical values recited herein include all values from the lower value to the upper value in increments of one unit provided that there is a separation of at least 2 units between any lower value and any higher value.
  • the amount of a component, a property, or a value of a process variable such as, for example, temperature, pressure, time and the like is, for example, from 1 to 90, preferably from 20 to 80, more preferably from 30 to 70
  • intermediate range values such as (for example, 15 to 85, 22 to 68, 43 to 51 , 30 to 32 etc.) are within the teachings of this specification.
  • individual intermediate values are also within the present teachings.

Abstract

L'invention concerne un tube d'échantillon de collecte de sang comprenant un matériau polymère thermoplastique ayant une barrière à l'humidité et un faible taux d'absorption d'humidité, une transparence optique pour permettre la visualisation d'un échantillon à l'intérieur du tube et une résistance chimique ; et éventuellement un revêtement transparent contenant du silicium sur une majorité de la paroi latérale du tube ; et un bouchon élastomère. Avant la collecte d'un échantillon de sang, la chambre creuse du tube est dans un état sous vide par rapport à une pression ambiante, et la chambre creuse est partiellement remplie d'un réactif dans un état initial, et le réactif est capable de conserver son état initial pendant une période d'au moins un mois sur une plage de température d'environ 2 °C à environ 30° C.
PCT/US2018/016867 2017-02-03 2018-02-05 Tube de collecte d'échantillon avec conservateur WO2018145005A1 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
CN201880023537.6A CN110520045A (zh) 2017-02-03 2018-02-05 带防腐剂的采样管
EP18747249.3A EP3576625A4 (fr) 2017-02-03 2018-02-05 Tube de collecte d'échantillon avec conservateur

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201762454451P 2017-02-03 2017-02-03
US201762454460P 2017-02-03 2017-02-03
US62/454,460 2017-02-03
US62/454,451 2017-02-03

Publications (1)

Publication Number Publication Date
WO2018145005A1 true WO2018145005A1 (fr) 2018-08-09

Family

ID=63041158

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2018/016867 WO2018145005A1 (fr) 2017-02-03 2018-02-05 Tube de collecte d'échantillon avec conservateur

Country Status (3)

Country Link
EP (1) EP3576625A4 (fr)
CN (1) CN110520045A (fr)
WO (1) WO2018145005A1 (fr)

Cited By (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109593824A (zh) * 2019-01-04 2019-04-09 宁波艾捷康宁生物科技有限公司 一种游离核酸保存剂及采血保存装置
CN109750087A (zh) * 2019-03-05 2019-05-14 温州广立生物医药科技有限公司 一种血液cfDNA提取试剂盒
CN109852539A (zh) * 2019-03-05 2019-06-07 温州广立生物医药科技有限公司 一种血液游离dna保存管
WO2020140035A1 (fr) 2018-12-27 2020-07-02 Streck, Inc. Procédés de préparation d'échantillons pour une analyse protéomique
CN111500704A (zh) * 2020-04-28 2020-08-07 广州市金圻睿生物科技有限责任公司 一种人胎儿染色体非整倍体检测试剂盒及方法
US20200316498A1 (en) * 2019-04-04 2020-10-08 Tai Diagnostics, Inc. Materials and methods for processing blood samples
WO2020227643A1 (fr) * 2019-05-09 2020-11-12 Truvian Sciences, Inc. Procédés et compositions pour inverser les dépôts de plaquettes
CN112322615A (zh) * 2020-11-18 2021-02-05 威高集团有限公司 核酸保存液、核酸提取保存液、采血管和提取核酸的方法
US20210060256A1 (en) * 2019-09-04 2021-03-04 Schott Schweiz Ag Dead end container and container assembly with dead end container
WO2022006260A1 (fr) 2020-07-01 2022-01-06 Streck, Inc. Procédés de préparation d'échantillons pour analyse protéomique
WO2023010059A1 (fr) * 2021-07-27 2023-02-02 Gateway Genomics, Llc Procédés, compositions et kits pour la conservation d'acides nucléiques
WO2023096739A1 (fr) * 2021-11-23 2023-06-01 Corning Incorporated Matériaux pour la manipulation et le stockage à long terme de vésicules extracellulaires
EP3989722A4 (fr) * 2019-06-28 2023-08-02 Zymo Research Corporation Compositions pour la stabilisation d'acides nucléiques acellulaires et leurs procédés

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111117999A (zh) * 2019-12-18 2020-05-08 上海兰卫医学检验所股份有限公司 一种适用于液态活检技术的血浆exRNA提取保存方法
CN111423975A (zh) * 2020-03-23 2020-07-17 重庆医科大学附属永川医院 一种可灭活病毒的真空采样管及其制备方法
CN111398006A (zh) * 2020-04-02 2020-07-10 苏州德沃生物技术有限公司 全血样本预处理装置
CN113391060B (zh) * 2021-05-15 2023-08-08 北京北方生物技术研究所有限公司 一种血液样本处理剂及其应用

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4040785A (en) * 1976-10-18 1977-08-09 Technicon Instruments Corporation Lysable blood preservative composition
WO2011110948A2 (fr) * 2010-03-11 2011-09-15 Antoine Turzi Procédé, tube et dispositif pour la préparation d'une composition de cicatrisation de blessure
WO2012108920A1 (fr) * 2011-02-09 2012-08-16 Natera, Inc Procédés de classification de ploïdie prénatale non invasive
CN102764133A (zh) * 2012-08-10 2012-11-07 上海科华检验医学产品有限公司 一种可直接分离血浆的真空采血管及其方法
CN104830831A (zh) * 2015-05-06 2015-08-12 厦门万基生物科技有限公司 一种保存外周血中游离dna的保存剂

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4308232A (en) * 1979-07-09 1981-12-29 Sherwood Medical Industries Inc. Anticoagulant stopper coating
JP2006502415A (ja) * 2002-10-10 2006-01-19 ベクトン・ディキンソン・アンド・カンパニー カスパーゼ阻害剤を有するサンプル収集システム
EP1816461B1 (fr) * 2002-10-16 2020-01-08 Streck Laboratories, Inc. Procédé et dispositif de collecte et de préservation de cellules pour analyse
US7378054B2 (en) * 2004-04-16 2008-05-27 Savvipharm Inc Specimen collecting, processing and analytical assembly
US20110300608A1 (en) * 2007-09-21 2011-12-08 Streck, Inc. Nucleic acid isolation in preserved whole blood
US20110143340A1 (en) * 2007-11-01 2011-06-16 Biocept, Inc. Non-invasive isolation of fetal nucleic acid
KR20120042748A (ko) * 2009-05-13 2012-05-03 씨브이 홀딩스 엘엘씨 코팅된 표면 검사를 위한 가스제거 방법
GB201303666D0 (en) * 2013-03-01 2013-04-17 Goldsborough Andrew S Sample fixation and stabilisation
US10091984B2 (en) * 2013-07-24 2018-10-09 Streck, Inc. Compositions and methods for stabilizing circulating tumor cells
CN105985904A (zh) * 2015-02-26 2016-10-05 付士明 循环游离dna真空采集管

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4040785A (en) * 1976-10-18 1977-08-09 Technicon Instruments Corporation Lysable blood preservative composition
WO2011110948A2 (fr) * 2010-03-11 2011-09-15 Antoine Turzi Procédé, tube et dispositif pour la préparation d'une composition de cicatrisation de blessure
WO2012108920A1 (fr) * 2011-02-09 2012-08-16 Natera, Inc Procédés de classification de ploïdie prénatale non invasive
CN102764133A (zh) * 2012-08-10 2012-11-07 上海科华检验医学产品有限公司 一种可直接分离血浆的真空采血管及其方法
CN104830831A (zh) * 2015-05-06 2015-08-12 厦门万基生物科技有限公司 一种保存外周血中游离dna的保存剂

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
S. V. KHAIDUKOV: "Protochnaya tsitometriya kak sovremennyi metod analiza v biologii i meditsine", MEDITSINSKAYA JMMUNILOGIYA, vol. 9, no. 4-5, 2007, pages 373 - 378, XP009516005, DOI: 10.15789/1563-0625-2007-4-5 *
See also references of EP3576625A4 *

Cited By (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020140035A1 (fr) 2018-12-27 2020-07-02 Streck, Inc. Procédés de préparation d'échantillons pour une analyse protéomique
CN109593824B (zh) * 2019-01-04 2022-03-18 宁波艾捷康宁生物科技有限公司 一种游离核酸保存剂及采血保存装置
CN109593824A (zh) * 2019-01-04 2019-04-09 宁波艾捷康宁生物科技有限公司 一种游离核酸保存剂及采血保存装置
CN109750087A (zh) * 2019-03-05 2019-05-14 温州广立生物医药科技有限公司 一种血液cfDNA提取试剂盒
CN109852539A (zh) * 2019-03-05 2019-06-07 温州广立生物医药科技有限公司 一种血液游离dna保存管
US11931674B2 (en) * 2019-04-04 2024-03-19 Natera, Inc. Materials and methods for processing blood samples
US20200316498A1 (en) * 2019-04-04 2020-10-08 Tai Diagnostics, Inc. Materials and methods for processing blood samples
WO2020227643A1 (fr) * 2019-05-09 2020-11-12 Truvian Sciences, Inc. Procédés et compositions pour inverser les dépôts de plaquettes
EP3989722A4 (fr) * 2019-06-28 2023-08-02 Zymo Research Corporation Compositions pour la stabilisation d'acides nucléiques acellulaires et leurs procédés
US20210060256A1 (en) * 2019-09-04 2021-03-04 Schott Schweiz Ag Dead end container and container assembly with dead end container
EP3789114A1 (fr) * 2019-09-04 2021-03-10 SCHOTT Schweiz AG Récipient à extrémité fermée et ensemble de récipients comprenant un récipient à extrémité fermée
CN112439108A (zh) * 2019-09-04 2021-03-05 肖特瑞士股份公司 封闭端容器和具有封闭端容器的容器组件
CN111500704B (zh) * 2020-04-28 2023-10-27 广州市金圻睿生物科技有限责任公司 一种人胎儿染色体非整倍体检测试剂盒及方法
CN111500704A (zh) * 2020-04-28 2020-08-07 广州市金圻睿生物科技有限责任公司 一种人胎儿染色体非整倍体检测试剂盒及方法
WO2022006260A1 (fr) 2020-07-01 2022-01-06 Streck, Inc. Procédés de préparation d'échantillons pour analyse protéomique
CN112322615A (zh) * 2020-11-18 2021-02-05 威高集团有限公司 核酸保存液、核酸提取保存液、采血管和提取核酸的方法
WO2023010059A1 (fr) * 2021-07-27 2023-02-02 Gateway Genomics, Llc Procédés, compositions et kits pour la conservation d'acides nucléiques
WO2023096739A1 (fr) * 2021-11-23 2023-06-01 Corning Incorporated Matériaux pour la manipulation et le stockage à long terme de vésicules extracellulaires

Also Published As

Publication number Publication date
EP3576625A1 (fr) 2019-12-11
EP3576625A4 (fr) 2020-12-16
CN110520045A (zh) 2019-11-29

Similar Documents

Publication Publication Date Title
WO2018145005A1 (fr) Tube de collecte d'échantillon avec conservateur
JP7293244B2 (ja) 溶血、凝固調節および細胞外小胞の安定化のための組成物
US11761025B2 (en) Preservation of cell-free nucleic acids
US8685748B2 (en) Devices and methods for collection, storage and transportation of biological specimens
EP2260942A2 (fr) Systeme de prélevement d'échantillion comprennant un inhibiteur de protease
US20140038172A1 (en) Matrix and System for Preserving Biological Specimens for Qualitative and Quantitative Analysis
CN102132140B (zh) 血液采集容器
US9949473B2 (en) Coagulation controlling agents and devices comprising the same
WO2014025787A1 (fr) Matrice et système pour la préservation d'échantillons biologiques pour une analyse qualitative et quantitative
EP2240280A1 (fr) Ensemble et procédé permettant d'améliorer le maintien sous vide de récipients d'échantillons à vide
US20230302454A1 (en) Sample collection containers, processes and collected samples
WO2009110488A1 (fr) Tube de collecte de sang
CN115362359A (zh) 样本采集容器

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 18747249

Country of ref document: EP

Kind code of ref document: A1

DPE1 Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101)
NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2018747249

Country of ref document: EP

Effective date: 20190903